Red flags have gone up regarding the vast overreach of Speaker Pelosi’s sweeping bill (H.R. 3), raising concerns that its key provisions that would enable the government to dictate prescription drug prices may be deemed unconstitutional.

In this first of a series of articles dedicated to the Women in Bio Boardroom Ready program, we discuss what the program entails and feedback from some previous participants.

Life sciences companies seeking to raise capital or form early partnerships with strategic players often make avoidable mistakes. Here are some tips that can increase your probability of a successful transaction.

What can make a company decide to enter new therapeutic entities into clinical development after decades as a dedicated supplier to bio research labs? Here we explain the reasons and implications of ArunA Bio’s decision.

When both members of a dual-career couple are in senior leadership roles, the challenges are intense. How couples face those challenges has consequences for their teams and organizations as well as for themselves and families.